

GILOTRIF (afatinib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic non-small cell lung cancer (NSCLC)
 - a. Confirmed non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test
2. Metastatic squamous non-small cell lung cancer
 - a. Confirmed non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test
 - b. Progressing after platinum-based chemotherapy
3. Advanced, recurrent, or persistent head and neck cancers
 - a. Used as single agent therapy
 - b. **NOT** used for nasopharyngeal cancer
 - c. Progression on or after platinum containing chemotherapy
4. Recurrent brain metastases
 - a. Confirmed non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test
 - b. Used as single agent therapy

Prior - Approval Limits

Quantity	20 mg	90 tablets per 90 days OR
	30 mg	90 tablets per 90 days OR
	40 mg	90 tablets per 90 days

Duration 12 months

GILOTRIF
(afatinib)

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic non-small cell lung cancer (NSCLC)
2. Metastatic squamous non-small cell lung cancer
3. Advanced, recurrent, or persistent head and neck cancers
4. Recurrent brain metastases

AND NONE of the following:

1. Development of life-threatening bullous, blistering, or exfoliating lesions
2. Confirmed interstitial lung disease (ILD)
3. Severe hepatic impairment

Prior – Approval *Renewal* Limits

Same as above